NMCC Clinical Trials: Recruiting

The listing below of clinical trials in use by New Mexico Cancer Center is primarily intended for medical and radiation oncologists, nurses and clinical trial coordinators. If you are a patient, we encourage you to discuss with your oncologist whether there are any clinical trials that might be of benefit to you. Unless otherwise noted, the information below, including Trial Status, Date Opened and Date Updated, is obtained from ClinicalTrials.gov. Complete detailed information including eligibility criteria for each trial is available by clicking the ClinicalTrials.gov link provided in that trial's Description Box.

Please contact us here for trial details: research@nmohc.com

Clinical Trials

 BREAST CANCER STUDIES

MK2870-012: Merck Sharp & Dohme LLC: A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery. NCT Identifier NCT06393374

RYZ101-001: A Phase 0 Multicenter Imaging Study of Hormone Receptor Negative (HR−) and Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer Using Somatostatin Receptor (SSTR)- targeted PET Imaging.

MK2870-011: Merck Sharp & Dohme LLC_TROFUSE-011: A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011). 

Stemline Therapeutics, Inc_STML-ELA-0422_Elegant: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence – A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)

TROPION_Breast05_D7630C0001: This is a research study looking at new treatment options for women with a specific type of aggressive breast cancer that has come back (locally recurrent) or spread to other parts of the body (metastatic).

EMBER-4_J2J-MC-JZLH_Eli Lilly and Company: This study is comparing two medications for people with early-stage breast cancer that is estrogen-receptor positive (ER+) and HER2-negative (HER2-)

CAMBRIA-2_D8535C00001: AstraZeneca: This study is testing a new medication called Camizestrant (AZD9833) for people with early-stage breast cancer.

 

LUNG CANCER STUDIES

TROPION-Lung17_D763QC00001: A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17)

 

PROSTATE CANCER STUDIES

CLP10: Clarity Pharmaceuticals Ltd_AMPLIFY: 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer. NCT Identifier NCT06970847

5541-CL-0201: Astellas Pharma Global Development, Inc.: A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer. NCT Identifier NCT07005154

FUSION FPI 2265-02: A Phase 2/3, Randomized, Open-Label, Multicenter Study to Evaluate The Safety and Efficacy of FPI-2254 (225 AC-PSMA-I&T) In Patients with PSMA-Positive mCRPC, Previously Treated with 177 Lu-PSMA Radioligand Therapy (RLT)

DORA Radium-223 Memorial Sloan Kettering: This study is testing a new combination treatment for men with prostate cancer that has spread to the bones.

BMS rechARge_CA071-1000: Celgene Corporation, a Bristol Myers Squibb Company: A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigator’s Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge

 

SKIN CANCER STUDIES

CTP-SCC-03: Alpha Tau Medical LTD.: This study is testing a new treatment option (Alpha DaRT224) for people with skin cancer that has come back (recurrent cutaneous squamous cell carcinoma). Click for more information.

 

MISCELLANEOUS STUDIES

Billion To One Northstar Response Clinical Validation Study NS-002: This study is looking to improve a test (NorthStar Response assay) used to see how well cancer treatments are working.

BEGIN Boston Gene BGER 001: This is a research study looking at the benefits of advanced genetic testing for people with advanced cancer.